Lab
Mercy Health Services-Iowa, Corp
Mercy Health Services-Iowa, Corp was paid $1.26M by Medicaid between Nov 2020 and Dec 2024, across 88 billing codes. Its largest line is 87637, Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV — 13% of everything it billed.
33Billing provider infoMERCY HEALTH SERVICES-IOWA, CORP
DUBUQUE, IA 52001
DUBUQUE, IA 52001
33aNPI1245846682assigned 09/21/2020
33bProvider typeClinical Medical Laboratory
28Total paid$1.26M
24GClaims81,260
24DCodes billed88
24AFirst – last monthNov 2020 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Iowa
Rank by total paid#9 of 35
Median peer was paid$42K
This provider vs. median30×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,762 | $13K | |
| 2021 | 19,332 | $395K | |
| 2022 | 21,030 | $372K | |
| 2023 | 21,350 | $256K | |
| 2024incomplete | 17,786 | $220K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 13% | 1,237 | 1,184 | $166K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 9.9% | 3,308 | 2,561 | $124K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.4% | 2,826 | 2,504 | $80K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.4% | 2,841 | 2,519 | $80K |
| 80050 | General health panel | 4.9% | 1,453 | 1,262 | $61K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.6% | 439 | 419 | $58K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.8% | 4,214 | 3,697 | $48K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.7% | 2,320 | 1,544 | $46K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.5% | 1,086 | 638 | $44K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.9% | 1,277 | 1,159 | $37K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.8% | 5,751 | 4,935 | $35K |
| 88142 | 2.4% | 2,164 | 1,892 | $30K |
76 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.4% | 1,448 | $30K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.4% | 1,213 | $30K |
| 87081 | 2.0% | 4,527 | $26K | |
| 36415 | Collection of venous blood by venipuncture | 2.0% | 6,939 | $25K |
| 80061 | Lipid panel | 1.9% | 2,725 | $24K |
| 83655 | 1.9% | 2,424 | $24K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 400 | $21K |
| 80053 | Comprehensive metabolic panel | 1.6% | 3,051 | $20K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.6% | 800 | $20K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.5% | 1,472 | $19K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 3,718 | $18K |
| 87077 | 1.4% | 2,734 | $17K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.2% | 806 | $16K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.1% | 35 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.0% | 2,161 | $13K |
| 87186 | <1% | 1,954 | $12K | |
| 84439 | <1% | 1,640 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 446 | $9K |
| 86780 | <1% | 760 | $8K | |
| 87071 | <1% | 1,047 | $8K | |
| 82607 | <1% | 628 | $7K | |
| 86480 | <1% | 114 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,047 | $5K |
| 82728 | <1% | 487 | $5K | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 1,211 | $5K |
| 84153 | <1% | 306 | $4K | |
| 86038 | <1% | 438 | $4K | |
| 87340 | <1% | 437 | $4K | |
| 83880 | <1% | 117 | $3K | |
| 86618 | <1% | 104 | $3K | |
| 84481 | <1% | 167 | $2K | |
| 87046 | <1% | 126 | $2K | |
| 86481 | <1% | 43 | $2K | |
| 87205 | <1% | 630 | $2K | |
| 86762 | <1% | 175 | $2K | |
| 87427 | <1% | 122 | $2K | |
| 87102 | <1% | 259 | $2K | |
| 86850 | <1% | 229 | $2K | |
| 85027 | <1% | 411 | $2K | |
| 81003 | <1% | 867 | $2K | |
| 81001 | <1% | 839 | $1K | |
| 86803 | <1% | 120 | $1K | |
| 87634 | <1% | 17 | $1K | |
| 83516 | <1% | 81 | $942.39 | |
| 84146 | <1% | 67 | $933.19 | |
| 83721 | <1% | 148 | $910.32 | |
| 85018 | <1% | 492 | $907.26 | |
| 83540 | <1% | 186 | $812.40 | |
| 87045 | <1% | 106 | $792.09 | |
| 81025 | <1% | 126 | $790.14 | |
| 84403 | <1% | 32 | $608.26 | |
| 80076 | <1% | 107 | $555.30 | |
| 82565 | <1% | 174 | $553.25 | |
| 80164 | <1% | 55 | $497.69 | |
| 87807 | <1% | 45 | $492.45 | |
| 84466 | <1% | 47 | $459.52 | |
| 86900 | <1% | 198 | $458.30 | |
| 86901 | <1% | 198 | $443.76 | |
| 85652 | <1% | 236 | $434.81 | |
| 83718 | <1% | 79 | $426.54 | |
| 85610 | <1% | 173 | $415.12 | |
| 87015 | <1% | 109 | $383.55 | |
| 82784 | <1% | 31 | $363.80 | |
| 87493 | <1% | 18 | $330.32 | |
| 86140 | <1% | 82 | $303.49 | |
| 84478 | <1% | 105 | $244.32 | |
| 82533 | <1% | 19 | $232.66 | |
| 87184 | <1% | 42 | $212.65 | |
| 86431 | <1% | 39 | $190.65 | |
| 83735 | <1% | 29 | $147.44 | |
| 82570 | <1% | 31 | $108.13 | |
| 82746 | <1% | 14 | $100.84 | |
| 82947 | <1% | 18 | $59.96 | |
| 87147 | <1% | 13 | $59.24 | |
| 84520 | <1% | 26 | $42.82 | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 24 | $11.73 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTAKES, KAY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Mercy Health Services-Iowa, Corp | Dubuque, IA | $489K |
| Mercy Family Pharmacy | Dubuque, IA | $188K |
| Mercy Family Pharmacy | Dubuque, IA | $65K |
| Mercy Family Pharmacy | Dubuque, IA | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.